Isabl
Cancer tests based on whole genome and transcriptome data.
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery. Isabl is a Y Combinator company (Winter 2020). YC-listed status: Active.
- Website
- isabl.io
- Location
- New York City, NY, USA; New York, NY, USA; Remote
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Isabl GxT — A whole-genome and transcriptome analysis platform for cancer that provides comprehensive tumor profiling beyond standard gene panels. · Saas · Enterprise
Links
- Y Combinator profileycombinator